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of centralised high-throughput laboratories, including 
eﬃ  cient systems for sample referral and results 
distribution, as well as regional hubs for bioinformatics 
will be crucial to increase the economies-of-scale while 
reducing costs.13
In conclusion, investments in the global HIV response 
should emphasise sustained viral suppression with ART 
not only to improve survival and reduce HIV transmission, 
but also to prevent large-scale HIV-drug resistance.
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Are we shifting attrition downstream in the HIV cascade?
As countries begin removing CD4 threshold barriers to 
antiretroviral therapy (ART) initiation (ie, treat all)1 for 
those with HIV, questions remain as to how countries 
will implement this strategy. Because numerous reviews 
have shown that retention in all stages of the HIV care 
cascade is less than optimal,2–5 one important question is 
whether changing ART eligibility criteria will, or should 
be, accompanied by interventions to improve retention 
within the HIV care cascade. In The Lancet HIV, Jack Olney 
and colleagues6 assessed this topic with intriguing 
results. 
With an individual-level microsimulation populated 
with data from Kenya, they found that a universal test-
and-treat approach alone (including seeking out those 
who are positive for HIV), although more eﬀ ective 
overall at reducing mortality, might not be as cost-
eﬀ ective as a combination of interventions targeted at 
improving the care cascade (including improved linkage, 
point-of-care CD4 testing, and outreach). This ﬁ nding is 
because the universal test-and-treat approach gets more 
patients into the health care cascade but it does not 
prevent leaks downstream in the cascade. This outcome 
begs the question, how much do we really know about 
interventions to improve the care cascade to inform 
mathematical models like this?
We still do not know whether the eﬀ ects of 
interventions designed to link and retain patients in 
HIV care are long-lasting, or if for some patients the 
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interventions simply put oﬀ  an inevitable loss from 
care. Olney and colleagues found that the package of 
interventions most eﬀ ective at reducing mortality 
are services designed to improve earlier stages of the 
cascade. But to improve the cascade overall, we must 
recognise that the barriers to entering care might not 
be the same as the barriers to initiating ART among 
those linked, which might not be the same as the 
barriers to remaining on ART long term. Singular 
approaches that target either a limited set of barriers 
or a single stage of the cascade are unlikely to maximise 
reductions in mortality and HIV transmission, and 
might be shifting attrition to later stages in the care 
cascade. This eﬀ ect is problematic for mathematical 
models because assumptions often need to be made 
that people who are prevented from dropping out 
of care by an intervention targeted at one stage are 
similar to those who already remained in care without 
intervention. This assumption seems unlikely to be the 
case as those prevented from dropping out of care early 
might be more likely to drop out later. If interventions 
are evaluated on the basis of short-term outcomes 
or focus on only a single stage in the care cascade (eg, 
linkage to care but not ART initiation), results will 
probably appear overly optimistic if these interventions 
simply shift losses from earlier in the cascade to later 
stages not studied.7 Therefore, long-term follow up of 
multifaceted approaches targeting multiple stages of 
the cascade are needed.
As we enter this new treat-all phase, we also have 
a chance to collect data to inform practice in the 
future. Published research on the HIV care cascade and 
interventions to improve it has several limitations, 
including absence of standardised outcome deﬁ nitions,8 
failure to account for so-called silent transfers,9 and a 
failure to track patients across multiple stages of care 
long term. Although numerous strategies have been 
proposed to improve retention of patients, evaluations 
of these interventions are scarce.10–13 More data are 
needed, particularly under routine conditions, but so 
are more robust evaluations. Focusing on standard 
deﬁ nitions, retention across multiple stages of care, and 
standardised follow-up periods will allow for improved 
decision making in the future.
Olney and colleagues noted that, “If greater synergy 
among interventions can be achieved than our model 
simulations, greater beneﬁ ts might be realised at lower 
costs.”6 Although true, the opposite might also be 
true. If patients who are helped by an intervention in 
one stage of the cascade are then more likely to drop 
out of care at a later stage, overall outcomes could be 
worse than predicted. Identiﬁ cation of new eﬀ ective 
approaches to improve retention throughout the care 
cascade and work to rigorously measure the combined 
beneﬁ ts of multifaceted approaches over the long term 
should be done to ensure that attrition is reduced, not 
simply delayed. 
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